Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy Participants

NCT03676322 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: M5049
DRUG: Placebo

Sponsor

Merck KGaA, Darmstadt, Germany